Allergic Rhinitis - Pipeline Review, H1 2015

Published: Jan, 2015 | Pages: 198 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Allergic Rhinitis - Pipeline Review, H1 2015

Summary

Global Markets Direct's, 'Allergic Rhinitis - Pipeline Review, H1 2015', provides an overview of the Allergic Rhinitis's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Allergic Rhinitis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Allergic Rhinitis and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Allergic Rhinitis
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Allergic Rhinitis and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Allergic Rhinitis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Allergic Rhinitis pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Allergic Rhinitis
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Allergic Rhinitis pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 7
Introduction 8
Global Markets Direct Report Coverage 8
Allergic Rhinitis Overview 9
Therapeutics Development 10
Pipeline Products for Allergic Rhinitis - Overview 10
Pipeline Products for Allergic Rhinitis - Comparative Analysis 11
Allergic Rhinitis - Therapeutics under Development by Companies 12
Allergic Rhinitis - Therapeutics under Investigation by Universities/Institutes 16
Allergic Rhinitis - Pipeline Products Glance 17
Late Stage Products 17
Clinical Stage Products 18
Early Stage Products 19
Allergic Rhinitis - Products under Development by Companies 20
Allergic Rhinitis - Products under Investigation by Universities/Institutes 26
Allergic Rhinitis - Companies Involved in Therapeutics Development 27
3M Drug Delivery Systems 27
Adamis Pharmaceuticals Corporation 28
ALK-Abello A/S 29
AnaptysBio, Inc. 30
Axikin Pharmaceuticals, Inc. 31
BioTech Tools s.a. 32
ELORAC, Inc. 33
FAES Farma SA 34
Fountain Biopharma Inc. 35
GenMont Biotech Inc. 36
GlaxoSmithKline plc 37
Glenmark Pharmaceuticals Ltd. 38
GlycoMar Limited 39
HAL Allergy BV 40
Hanmi Pharmaceuticals, Co. Ltd. 41
Hisamitsu Pharmaceutical Co., Inc. 42
Johnson & Johnson 43
Laboratorios LETI S.L. 44
Ligand Pharmaceuticals, Inc. 45
Marinomed Biotechnologie GmbH 46
Merck & Co., Inc. 47
Mitsubishi Tanabe Pharma Corporation 48
Nektar Therapeutics 49
NeoPharm Co., Ltd. 50
Novartis AG 51
Nuvo Research Inc. 52
Ono Pharmaceutical Co., Ltd. 53
Oxagen Limited 54
Panmira Pharmaceuticals, LLC. 55
Pfizer Inc. 56
Protectimmun GmbH 57
Revance Therapeutics, Inc. 58
Rottapharm SpA 59
Shionogi & Co., Ltd. 60
Stallergenes S.A. 61
Sun Pharma Advanced Research Company Ltd. 62
Trimel BioPharma SRL 63
VentiRx Pharmaceuticals, Inc. 64
Xencor, Inc. 65
Ziarco Pharma Ltd 66
Allergic Rhinitis - Therapeutics Assessment 67
Assessment by Monotherapy Products 67
Assessment by Combination Products 68
Assessment by Target 69
Assessment by Mechanism of Action 71
Assessment by Route of Administration 73
Assessment by Molecule Type 75
Drug Profiles 77
(azelastine hydrochloride + mometasone furoate) - Drug Profile 77
(fluticasone furoate + levocabastine hydrochloride) - Drug Profile 78
(GSP 301-1 NS + GSP 301-2 NS) - Drug Profile 79
(montelukast sodium + levocetirizine dihydrochloride) - Drug Profile 80
854-A - Drug Profile 81
Allergen for Birch Pollen Induced Allergic Rhinitis and Rhinoconjunctivitis - Drug Profile 82
Allergen for House Dust Mites Induced Allergic Rhinitis and Rhinoconjunctivitis - Drug Profile 83
Allergen for Pollen Grass Allergy Induced Allergic Rhinitis and Rhinoconjunctivitis - Drug Profile 85
allergenic pollen extract of timothy - Drug Profile 86
AM-211 - Drug Profile 87
AM-461 - Drug Profile 89
ANB-020 - Drug Profile 91
andolast - Drug Profile 92
APC-3000 - Drug Profile 93
Arabinogalactan - Drug Profile 94
AVANZ Olive Immunotherapy for Allergic Rhinitis - Drug Profile 95
Avanz Phleum Pratense - Drug Profile 96
bepotastine besylate - Drug Profile 97
bilastine - Drug Profile 99
budesonide - Drug Profile 100
C-525 - Drug Profile 101
CBP-174 - Drug Profile 102
cidoxepin hydrochloride - Drug Profile 103
Depigoid Birch - Drug Profile 104
Dermatophagoides Pteronyssinus Allergen Extract - Drug Profile 105
desloratadine - Drug Profile 106
Drug for Japanese Cedar Pollen Allergy - Drug Profile 107
esketamine - Drug Profile 108
FB-825 - Drug Profile 110
fevipiprant - Drug Profile 111
fluticasone furoate - Drug Profile 113
GLY-079 - Drug Profile 116
GLY-145 - Drug Profile 117
GMNL-32 - Drug Profile 118
gpASIT + TM - Drug Profile 119
GSK-2245035 - Drug Profile 121
HP-3060 - Drug Profile 123
Lactococcus lactis G121 - Drug Profile 124
levocabastine hydrochloride - Drug Profile 125
MAM-06301 - Drug Profile 126
MK-8237 - Drug Profile 127
NKTR-125 - Drug Profile 128
NPB-3 - Drug Profile 129
OC-2417 - Drug Profile 130
OC-459 - Drug Profile 131
Olea Europaea Pollen Extract - Drug Profile 133
ONO-4053 - Drug Profile 134
PF-06444752 - Drug Profile 135
PF-06444753 - Drug Profile 136
rBet v1 - Drug Profile 137
rE58 - Drug Profile 139
RT-001 - Drug Profile 140
S-524101 - Drug Profile 142
S-555739 - Drug Profile 144
Small Molecule for Allergic Rhinitis - Drug Profile 145
Small Molecule to Antagonize G Protein Coupled Receptors for Respiratory Disorders - Drug Profile 146
Small Molecules to Inhibit Histamine H3 Receptor for Nasal Congestion and Allergic Rhinitis - Drug Profile 147
Small Molecules to Inhibit PGD2 Synthase for Asthma and Allergic Rhinitis - Drug Profile 148
Small Molecules to Inhibit Spleen Tyrosine Kinase for Allergic Inflammatory Disorders - Drug Profile 149
SUN-0597 - Drug Profile 150
SUNL-731 - Drug Profile 152
TBS-6 - Drug Profile 153
Vaccine for Allergic Rhinitis and Allergic Asthama - Drug Profile 154
VAK-694 - Drug Profile 155
VTX-1463 - Drug Profile 157
VTX-378 - Drug Profile 158
WF-10 - Drug Profile 159
WF-10 liposomal - Drug Profile 161
XmAb-7195 - Drug Profile 162
ZPL-868087 - Drug Profile 163
Allergic Rhinitis - Recent Pipeline Updates 164
Allergic Rhinitis - Dormant Projects 176
Allergic Rhinitis - Discontinued Products 183
Allergic Rhinitis - Product Development Milestones 185
Featured News & Press Releases 185
Appendix 192
Methodology 192
Coverage 192
Secondary Research 192
Primary Research 192
Expert Panel Validation 192
Contact Us 193
Disclaimer 193

List of Tables
Number of Products under Development for Allergic Rhinitis, H1 2015 15
Number of Products under Development for Allergic Rhinitis - Comparative Analysis, H1 2015 16
Number of Products under Development by Companies, H1 2015 18
Number of Products under Development by Companies, H1 2015 (Contd..1) 19
Number of Products under Development by Companies, H1 2015 (Contd..2) 20
Number of Products under Investigation by Universities/Institutes, H1 2015 21
Comparative Analysis by Late Stage Development, H1 2015 22
Comparative Analysis by Clinical Stage Development, H1 2015 23
Comparative Analysis by Early Stage Development, H1 2015 24
Products under Development by Companies, H1 2015 25
Products under Development by Companies, H1 2015 (Contd..1) 26
Products under Development by Companies, H1 2015 (Contd..2) 27
Products under Development by Companies, H1 2015 (Contd..3) 28
Products under Development by Companies, H1 2015 (Contd..4) 29
Products under Development by Companies, H1 2015 (Contd..5) 30
Products under Investigation by Universities/Institutes, H1 2015 31
Allergic Rhinitis - Pipeline by 3M Drug Delivery Systems, H1 2015 32
Allergic Rhinitis - Pipeline by Adamis Pharmaceuticals Corporation, H1 2015 33
Allergic Rhinitis - Pipeline by ALK-Abello A/S, H1 2015 34
Allergic Rhinitis - Pipeline by AnaptysBio, Inc., H1 2015 35
Allergic Rhinitis - Pipeline by Axikin Pharmaceuticals, Inc., H1 2015 36
Allergic Rhinitis - Pipeline by BioTech Tools s.a., H1 2015 37
Allergic Rhinitis - Pipeline by ELORAC, Inc., H1 2015 38
Allergic Rhinitis - Pipeline by FAES Farma SA, H1 2015 39
Allergic Rhinitis - Pipeline by Fountain Biopharma Inc., H1 2015 40
Allergic Rhinitis - Pipeline by GenMont Biotech Inc., H1 2015 41
Allergic Rhinitis - Pipeline by GlaxoSmithKline plc, H1 2015 42
Allergic Rhinitis - Pipeline by Glenmark Pharmaceuticals Ltd., H1 2015 43
Allergic Rhinitis - Pipeline by GlycoMar Limited, H1 2015 44
Allergic Rhinitis - Pipeline by HAL Allergy BV, H1 2015 45
Allergic Rhinitis - Pipeline by Hanmi Pharmaceuticals, Co. Ltd., H1 2015 46
Allergic Rhinitis - Pipeline by Hisamitsu Pharmaceutical Co., Inc., H1 2015 47
Allergic Rhinitis - Pipeline by Johnson & Johnson, H1 2015 48
Allergic Rhinitis - Pipeline by Laboratorios LETI S.L., H1 2015 49
Allergic Rhinitis - Pipeline by Ligand Pharmaceuticals, Inc., H1 2015 50
Allergic Rhinitis - Pipeline by Marinomed Biotechnologie GmbH, H1 2015 51
Allergic Rhinitis - Pipeline by Merck & Co., Inc., H1 2015 52
Allergic Rhinitis - Pipeline by Mitsubishi Tanabe Pharma Corporation, H1 2015 53
Allergic Rhinitis - Pipeline by Nektar Therapeutics, H1 2015 54
Allergic Rhinitis - Pipeline by NeoPharm Co., Ltd., H1 2015 55
Allergic Rhinitis - Pipeline by Novartis AG, H1 2015 56
Allergic Rhinitis - Pipeline by Nuvo Research Inc., H1 2015 57
Allergic Rhinitis - Pipeline by Ono Pharmaceutical Co., Ltd., H1 2015 58
Allergic Rhinitis - Pipeline by Oxagen Limited, H1 2015 59
Allergic Rhinitis - Pipeline by Panmira Pharmaceuticals, LLC., H1 2015 60
Allergic Rhinitis - Pipeline by Pfizer Inc., H1 2015 61
Allergic Rhinitis - Pipeline by Protectimmun GmbH, H1 2015 62
Allergic Rhinitis - Pipeline by Revance Therapeutics, Inc., H1 2015 63
Allergic Rhinitis - Pipeline by Rottapharm SpA, H1 2015 64
Allergic Rhinitis - Pipeline by Shionogi & Co., Ltd., H1 2015 65
Allergic Rhinitis - Pipeline by Stallergenes S.A., H1 2015 66
Allergic Rhinitis - Pipeline by Sun Pharma Advanced Research Company Ltd., H1 2015 67
Allergic Rhinitis - Pipeline by Trimel BioPharma SRL, H1 2015 68
Allergic Rhinitis - Pipeline by VentiRx Pharmaceuticals, Inc., H1 2015 69
Allergic Rhinitis - Pipeline by Xencor, Inc., H1 2015 70
Allergic Rhinitis - Pipeline by Ziarco Pharma Ltd, H1 2015 71
Assessment by Monotherapy Products, H1 2015 72
Assessment by Combination Products, H1 2015 73
Number of Products by Stage and Target, H1 2015 75
Number of Products by Stage and Mechanism of Action, H1 2015 77
Number of Products by Stage and Route of Administration, H1 2015 79
Number of Products by Stage and Molecule Type, H1 2015 81
Allergic Rhinitis Therapeutics - Recent Pipeline Updates, H1 2015 169
Allergic Rhinitis - Dormant Projects, H1 2015 181
Allergic Rhinitis - Dormant Projects (Contd..1), H1 2015 182
Allergic Rhinitis - Dormant Projects (Contd..2), H1 2015 183
Allergic Rhinitis - Dormant Projects (Contd..3), H1 2015 184
Allergic Rhinitis - Dormant Projects (Contd..4), H1 2015 185
Allergic Rhinitis - Dormant Projects (Contd..5), H1 2015 186
Allergic Rhinitis - Dormant Projects (Contd..6), H1 2015 187
Allergic Rhinitis - Discontinued Products, H1 2015 188
Allergic Rhinitis - Discontinued Products (Contd..1), H1 2015 189